TY - JOUR
T1 - New Paradigms to Help Decisions in Treatment Choice
T2 - Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases
AU - Loy, Laura
AU - Fiorino, Gionata
AU - Roda, Giulia
AU - Allocca, Mariangela
AU - Furfaro, Federica
AU - Zilli, Alessandra
AU - Gilardi, Daniela
AU - Radice, Simona
AU - Peyrin-Biroulet, Laurent
AU - Danese, Silvio
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
PY - 2020/12/11
Y1 - 2020/12/11
N2 - The increasing armamentarium of drugs for inflammatory bowel disease (IBD) requires a direct comparison of different therapeutic options in order to guide physicians in the choice of the most appropriate treatment for their patients. Head-to-head trials, considered the gold standard in comparative research in IBD, allow to compare different therapies in the same population and setting, but also to evaluate different treatment strategies. Despite head-to-head trials including biologics and immunosuppressive therapy in IBD have been performed decades ago, the interest of these direct comparison is growing since the publication of the first randomized controlled trial directly comparing biologic agents with different molecular targets. This review provides an overview of the past and current IBD head-to-head trial, considering their respective strengths and limitations in a real-life setting.
AB - The increasing armamentarium of drugs for inflammatory bowel disease (IBD) requires a direct comparison of different therapeutic options in order to guide physicians in the choice of the most appropriate treatment for their patients. Head-to-head trials, considered the gold standard in comparative research in IBD, allow to compare different therapies in the same population and setting, but also to evaluate different treatment strategies. Despite head-to-head trials including biologics and immunosuppressive therapy in IBD have been performed decades ago, the interest of these direct comparison is growing since the publication of the first randomized controlled trial directly comparing biologic agents with different molecular targets. This review provides an overview of the past and current IBD head-to-head trial, considering their respective strengths and limitations in a real-life setting.
U2 - 10.2174/1389450121666201211162527
DO - 10.2174/1389450121666201211162527
M3 - Article
C2 - 33308131
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
ER -